TRIENTINE

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Cuprior®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Orphalan
Condition/indication:
(therapeutic use)
  • Wilson disease
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New listing (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
May 2022 PBAC meeting
Opportunity for consumer comment:
Open 24/11/2021 and close 27/01/2022 (see PBS Website)
PBAC meeting:
Held on 06/05/2022
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – May 2022
Case ID
a569
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19